Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide
(2018) In Endocrine 62(3). p.737-739
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1d38974c-c835-45ee-8c25-56635ade072f
- author
- organization
- publishing date
- 2018-09-24
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Endocrine
- volume
- 62
- issue
- 3
- pages
- 737 - 739
- publisher
- Humana Press
- external identifiers
-
- scopus:85053657322
- pmid:30246233
- ISSN
- 1355-008X
- DOI
- 10.1007/s12020-018-1751-9
- language
- English
- LU publication?
- yes
- id
- 1d38974c-c835-45ee-8c25-56635ade072f
- date added to LUP
- 2018-10-24 16:16:35
- date last changed
- 2024-08-06 01:50:13
@article{1d38974c-c835-45ee-8c25-56635ade072f, author = {{Bengtsson, D. and Schrøder, H. D. and Berinder, K. and Maiter, D. and Hoybye, C. and Ragnarsson, O. and Feldt-Rasmussen, U. and Krogh Rasmussen, Å. and van der Lely, A. and Petersson, M. and Johannsson, G. and Andersen, M. and Burman, P.}}, issn = {{1355-008X}}, language = {{eng}}, month = {{09}}, number = {{3}}, pages = {{737--739}}, publisher = {{Humana Press}}, series = {{Endocrine}}, title = {{Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide}}, url = {{http://dx.doi.org/10.1007/s12020-018-1751-9}}, doi = {{10.1007/s12020-018-1751-9}}, volume = {{62}}, year = {{2018}}, }